Stocks Dive as US War Plans on Iran Spark Market Turmoil
March 21, 2026, 1:23 AM EDT. Stocks plunged sharply Friday with the S&P 500, Dow Jones Industrial Average, and Nasdaq 100 hitting 6.25-month lows amid escalating US-Iran tensions. Pentagon plans for possible US ground troop deployment and control of Iran's Kharg Island fanned fears. Elevated energy costs from the Iran conflict, disrupting 7.5% of global oil supply, pressured inflation and growth outlooks. Crude oil prices remain high despite emergency stock releases. Global bond yields rose, with the US 10-year Treasury yield hitting a 7.5-month peak at 4.39%. The market factors a 12% chance of a Federal Reserve interest rate hike in April amid volatility. Overseas markets tumbled too, with Euro Stoxx 50 closing down 2%. The conflict's extension casts a shadow over energy markets and investor sentiment.
New Hope (ASX:NHC) Maintains Dividends Despite Profit Drop, Reframes Capital Allocation Strategy
March 21, 2026, 1:22 AM EDT. New Hope Corporation reported a net income of A$54.3 million and basic EPS of A$0.064 for the half-year ending January 2026, down from prior results amid weaker coal prices. The company declared a fully franked interim dividend of A$0.10 per share and extended a A$100 million share buyback program to March 2027, underlining a focus on capital returns despite reduced earnings. Management is ramping production at the New Acland Mine, aiming to sustain volumes. Analysts note coal price volatility remains the primary risk, with forecasts for 2028 earnings and revenue seeing downward revisions, impacting valuation views. The dividend and buyback support an income story, yet investors must weigh this against potential further pressure on profits and market risks.
Pfizer Ltd Stock Faces Challenges Amid Indian Pharma Market Shifts and Global Parent Pressures
March 21, 2026, 1:21 AM EDT. Pfizer Ltd, the Indian arm of Pfizer Inc., is experiencing share price volatility on NSE and BSE due to sector-wide challenges and strategic shifts by its global parent. The stock trades near ?4,738, down 4% year-over-year, underperforming the Nifty Pharma index. Investor concerns include regulatory changes, supply chain issues, and premium valuations with a high price-to-earnings ratio over 177. Despite recent modest gains and vaccine launches like the 20-valent Pneumococcal vaccine, Pfizer Ltd faces execution risks within India's complex pharma landscape. Its market cap stands around ?24,300 crore. European investors, especially in Germany, Austria, and Switzerland, should monitor developments closely amid India's evolving healthcare market and regulatory environment.
London Stock Exchange Offers Strong 2026 Forecast and Attractive Shareholder Yield
March 21, 2026, 1:20 AM EDT. The London Stock Exchange Group (LSE) has issued solid guidance for 2026, underpinned by a robust business model. Analysts highlight the company's shareholder yield, which exceeds 8%, making LSE shares appealing for income-focused investors. The strong 2026 outlook reflects expectations of steady revenue growth and disciplined cost management. Additionally, LSE's diversified revenue streams from trading, clearing, and data services provide stability amid market volatility. Despite market uncertainties, the solid guidance coupled with an attractive yield supports analyst buy ratings. Investors are advised to consider LSE's long-term fundamentals and current valuation when assessing potential allocations to the stock. The analysis is based on an optimistic yet cautious view of LSE's financial prospects and capital return strategy.
Abbott Laboratories (ABT) Shares Dip Amid Valuation Debate: Is This a Buying Opportunity?
March 21, 2026, 1:04 AM EDT. Abbott Laboratories' (ABT) share price has declined 15% year-to-date, trading around US$105, sparking debate on whether it's a value trap or a long-term opportunity. Analysis using discounted cash flow (DCF) models estimates the stock's intrinsic value at approximately $164.42 per share, signalling a potential 35.9% undervaluation. The healthcare giant's recent performance lags peers amid investor caution over medical equipment demand and capital allocation strategies. Analyst forecasts project free cash flow reaching $11.46 billion by 2028, supporting bullish valuation metrics despite recent stock weakness. Investors are advised to consider these fundamentals alongside sector risks when assessing ABT shares.
Corn Futures Slip Amid Strong Export Sales
March 21, 2026, 12:35 AM EDT. Corn futures dropped 3 to 4 cents on Friday, with the front-month contracts retreating amid steady export demand. The national average cash corn price fell around 3.75 cents to $4.23 per bushel. Export sales data showed marketing-year commitments reached 67.658 million metric tons (MMT), up 30% year-on-year and tracking closely to USDA targets. Shipments totaled 43.46 MMT, outperforming the typical pace at 52% of USDA projections. The Buenos Aires Grain Exchange reported Argentina's corn harvest 13% completed. May 2026 corn prices slipped to $4.66, while December contracts edged down to $4.90. Market watchers note strong export fundamentals but a cautious tone as prices fade lightly ahead of further crop updates.
Accenture Shares Down 33%: Is the Stock Undervalued Now?
March 21, 2026, 12:34 AM EDT. Accenture's (ACN) share price has slid 33% over the past year, closing at $199.99 recently. Despite this decline, a Discounted Cash Flow (DCF) analysis values the stock at $302.70 per share, suggesting it is undervalued by nearly 34%. The DCF method estimates future cash flows discounted to present value, indicating potential upside. Meanwhile, Accenture's Price-to-Earnings (P/E) ratio stands at 16.05x, below the IT sector average of 19.37x, reflecting market caution amid broader tech sector reassessments. Investors are weighing Accenture's strong position in digital transformation and AI services against its recent underperformance. The divergence between valuation models and market price invites reconsideration of the stock's appeal for long-term investors.
Safran Stock Pullback Presents Potential Undervaluation, DCF Model Shows
March 21, 2026, 12:33 AM EDT. Safran's share price recently dropped by 18.9% over 30 days, despite a strong 1-year return of 13.7% and 3-year return of 117.9%. The aerospace and defense company faces sector-specific pressures, including contract flows and regulatory factors. A Discounted Cash Flow (DCF) analysis by Simply Wall St values Safran shares at €379.33, about 25.8% higher than the current €281.60 price, suggesting undervaluation. Safran scores a perfect 6 out of 6 on valuation measures, highlighting a potential buying opportunity for investors. The DCF model projects free cash flow growing from €4.0 billion last year to €9.9 billion by 2035, underlining expectations of future profitability. Investors weigh this alongside a 7.5% weekly decline and broader market sentiment in aerospace. Safran remains a key player worth watching amid recent market volatility.
Enbridge: A 5.2% Yield Dividend Stock Ideal for TFSA Investors
March 21, 2026, 12:19 AM EDT.Enbridge (TSX:ENB) stands out as a top TSX stock for Tax-Free Savings Accounts (TFSA), offering a 5.2% dividend yield with a long history of steady payouts and growth. The energy infrastructure giant has increased dividends at a compound annual growth rate of 9% since 1995, underpinned by a low-risk, diversified asset base generating stable distributable cash flow. With over 200 high-quality assets and a significant portion of earnings coming from regulated or long-term contracts, Enbridge limits exposure to commodity price swings. The company's recent 3% dividend hike to $0.97 per share quarterly signals ongoing income stability and potential growth, making it attractive for investors seeking reliable, tax-free cash flow amid market volatility.
Trisura Group Shares Dip 0.5% Amid Robust Analyst Upgrades
March 21, 2026, 12:18 AM EDT. Trisura Group Ltd (TSE:TSU) saw its stock price fall 0.5% on Friday, reaching C$43.00 during mid-day trading, despite a surge in volume by 639%. The Canadian specialty insurance firm's shares remain favored, with six analysts rating it as a Buy and price targets averaging C$55.13. Notably, Cormark and Canadian Imperial Bank of Commerce recently boosted their price targets and ratings, reflecting confidence in Trisura's growth. The company reported C$0.75 earnings per share last quarter, with a 5.51% net margin and strong return on equity at 16.3%. Trisura's market cap stands at C$2.05 billion with a low beta of 0.34, indicating less volatility than the market. Analysts expect 3.13 EPS for the current fiscal year, underscoring solid financial prospects despite the slight stock price dip.
UniFirst (UNF) Valuation At Odds With Strong 90-Day Stock Surge
March 21, 2026, 12:02 AM EDT. UniFirst (UNF) shares closed at $260.76 after a robust 53.24% gain over 90 days, drawing investor attention to its $2.45 billion revenue and $139.53 million net income from uniform and safety services. Despite a recent 1.79% daily dip, UniFirst's 1-year shareholder return stands at 33.18%. The stock trades near analyst targets but appears 12% overvalued against a fair value estimate of $232, reflecting a 6.98% discount rate. Analysts' consensus price target is $178.25, with forecasts varying from $152 to $194, signaling mixed views on growth and margins. Risks include declining usage levels and rising healthcare costs, potentially affecting revenue and margins. Investors are advised to assess these dynamics and broader market options before making decisions.
